Matthew Germinaro Selected Research

guselkumab

12/2023	Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
1/2023	Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
1/2022	Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthew Germinaro Research Topics

Disease

4	Asthma (Bronchial Asthma) 01/2019 - 10/2016
2	Ulcerative Colitis 12/2023 - 01/2023
1	Hemorrhage 12/2023
1	Poisoning 01/2023
1	Colonic Neoplasms (Colon Cancer) 01/2023
1	COVID-19 01/2023
1	Tuberculosis (Tuberculoses) 01/2023
1	Crohn Disease (Crohn's Disease) 01/2022
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022
1	Psoriatic Arthritis 01/2022
1	Peanut Hypersensitivity (Peanut Allergy) 12/2019
1	Nasal Polyps (Nasal Polyp) 01/2019
1	Rhinosinusitis 01/2019
1	Common Variable Immunodeficiency 07/2015

Drug/Important Bio-Agent (IBA)

4	Monoclonal AntibodiesIBA 01/2023 - 10/2016
4	reslizumabIBA 01/2019 - 10/2016
3	guselkumabIBA 12/2023 - 01/2022
2	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2023 - 10/2016
1	Immunosuppressive Agents (Immunosuppressants)IBA 12/2023
1	golimumab FDA Link 01/2023
1	Interleukin-23 (Interleukin 23)IBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Immunoglobulin E (IgE)IBA 12/2019
1	hypoxanthine arabinoside (ara-H)IBA 12/2019
1	EpitopesIBA 12/2019
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2019
1	3- (2- (4- azidobenzamidino)ethyl)- 5- hydroxyindole (SABA)IBA 10/2016
1	B-Cell Activation Factor ReceptorIBA 07/2015

Therapy/Procedure

4	Therapeutics 12/2023 - 10/2016
1	Biological Therapy 01/2022
1	Immunotherapy 12/2019